THAZ

THAZ
Clinical data
Drug classGABAA-ρ receptor antagonist; GABAA receptor antagonist; Glycine receptor antagonist
ATC code
  • None
Identifiers
  • 5,6,7,8-tetrahydro-4H-[1,2]oxazolo[4,5-d]azepin-3-one
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC7H10N2O2
Molar mass154.169 g·mol−1
3D model (JSmol)
  • C1CNCCC2=C1C(=O)NO2
  • InChI=1S/C7H10N2O2/c10-7-5-1-3-8-4-2-6(5)11-9-7/h8H,1-4H2,(H,9,10)
  • Key:KHTRGFVHYPWHIZ-UHFFFAOYSA-N

THAZ, also known as 5,6,7,8-tetrahydro-4H-isoxazolo(4,5-d)azepin-3-ol, is a moderately potent GABAA-ρ receptor antagonist related to gaboxadol (THIP). Unlike gaboxadol, it is said to be virtually inactive at the GABAA receptor. However, in other studies, it showed significant affinity for the GABAA receptor, where it appeared to act as an antagonist. In addition to its GABAA-ρ receptor antagonism, THAZ is a very weak glycine receptor antagonist. In contrast to muscimol and gaboxadol, THAZ injected directly into the brain produced convulsions. The drug was first described in the scientific literature by Povl Krogsgaard-Larsen and colleagues by 1979. Derivatives of THAZ such as N-Bn-THAZ and O-Bn-THAZ have been found to act as serotonin 5-HT2A and 5-HT2C receptor agonists.

See also